Narrative reviewindependent cross-checkabstract checked I-CAN-121 standard review
Cancer patients do make antibodies against their tumours
p53 Antibodies in the sera of patients with various types of cancer: a review.
Overview
Soussi T. Cancer Res 2000 · PMID 10766157
About 30% of cancer patients have antibodies against the tumour protein p53.
Does the study support the specific claim? No · Methodological quality: low
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Review p53 antibodies.
- How was the study done?
Narrative review.
- How many people, animals or samples were studied?
>130 studies.
- What was actually found?
Antibodies common in cancer patients.
- How large was the observed effect?
Specificity 96%, sensitivity 30%.
- What do the results mean in everyday life?
The immune system notices cancer, though it may not stop it.
- What are the study's limitations?
Older narrative review.
- What does it say about Elawady's specific claim?
Refutes 'no antibodies form'.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That antibodies control tumours.
Scientific in-depth review
1. Full reference
- Authors
- Soussi T
- Journal
- Cancer Res
- Year
- 2000
- Identifier
- PMID 10766157
- Verification
- verified – PubMed efetch 2026-10-26
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
Occurrence and meaning of p53 antibodies in cancer patients
3. Study design and population
- Study design
- Narrative review – Narrative review of >130 studies on serum p53 antibodies
- Population
Cancer patients and high-risk individuals
- Country
International
- Period
Studies 1992-1999
- Sample size
>130 papers
- Inclusion and exclusion criteria
Studies of serum p53 antibodies
4. Methods and endpoints
- Exposure / intervention
Cancer / p53 mutation
- Comparator
Healthy controls
- Endpoints
p53 antibody presence
- Statistical methods
Narrative compilation
5. Actual results
- Results
p53 antibodies are found predominantly in cancer patients (specificity 96%; sensitivity about 30%); they result from self-immunisation against accumulated mutant p53; associated with high-grade tumours and poor survival in several cancers.
- Absolute risks
not applicable
- Authors' conclusion
p53 antibodies reflect a humoral immune response to tumours; potential for early detection.
6. Strengths
- Large body of studies
7. Weaknesses
- Narrative review; older
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Narrative review.
9. Assessment of the statistical interpretation
Not applicable.
10. Relevance to the specific claim
Directly refutes 'no antibodies form against cancer'; also shows antibodies alone do not eliminate tumours (associated with poor prognosis).
11. Independent contrary findings
Antibody formation does not equal effective tumour control - a nuance that partly fits Elawady's observation.
12. Transferability to Germany and Europe
High.
13. Overall methodological judgement
Refutes the factual premise of the claim.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | low |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
15. Linked fact checks
- The immune system does not fight cancer (no antibodies form against it), which shows the body accepts the tumour; therefore attacking it with chemotherapy is wrong. – Studies contradicting or limiting the claim